API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2022/08/15/2498526/32478/en/Calithera-Biosciences-Reports-Second-Quarter-2022-Financial-Results-and-Recent-Highlights.html
https://www.thepharmaletter.com/article/two-new-drugs-add-harmony-to-calithera-s-precision-pipeline?__cf_chl_jschl_tk__=pmd_x66vxwinkDHJdlA02hF8AvCwosLXtWK1gLCV4NmksrM-1634712524-0-gqNtZGzNApCjcnBszQs9
https://endpts.com/slammed-with-phii-flop-for-lead-drug-calithera-lays-off-a-third-of-its-staffers/
https://www.globenewswire.com/news-release/2020/11/04/2120344/0/en/Calithera-Biosciences-Announces-Expansion-of-Ongoing-Clinical-Trial-Evaluating-Telaglenastat-in-Combination-with-palbociclib-IBRANCE.html
https://globenewswire.com/news-release/2019/02/04/1709700/0/en/Calithera-Biosciences-Completes-Patient-Enrollment-in-Randomized-Phase-2-ENTRATA-Trial-of-Telaglenastat-CB-839-and-Everolimus-in-Renal-Cell-Carcinoma.html